Oncternal Therapeutics
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Oncternal Therapeutics's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 47% to $785,000. The net income raised on -$39,479,000 and profit margin reached -5029%. Total operating expenses were $12,746,000.
Profit Margin
| 2014 | 0 | -39.41M | |
|---|---|---|---|
| 2015 | 0 | -18.70M | |
| 2016 | 0 | -17.72M | |
| 2017 | 1.67M | -30.43M | -1818.34% |
| 2018 | 0 | -38.41M | |
| 2019 | 2.42M | -15.91M | -656.16% |
| 2020 | 3.37M | -17.20M | -509.9% |
| 2021 | 4.31M | -31.3M | -725.38% |
| 2022 | 1.49M | -43.39M | -2912.28% |
| 2023 | 785K | -39.47M | -5029.17% |
ONCT Income Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||
Revenue | 785K | 1.49M | 4.31M | 3.37M | 2.42M | 0 | 1.67M | 0 | 0 | 0 |
Cost of revenue | 29.75M | 179K | 169K | 12M | 10.15M | 0 | 47K | 2.51M | 43K | 0 |
Gross profit | -28.96M | 1.31M | 4.14M | -8.62M | -7.73M | 0 | 1.62M | -2.51M | -43K | 0 |
Operating exp. | ||||||||||
Research and development | 29.75M | 32.98M | 24.08M | 12.54M | 10.15M | 29.66M | 21.46M | 17.22M | 13.60M | 20.87M |
Selling and marketing | 200K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 12.74M | 44.94M | 31.36M | 17.54M | 15.02M | 39.05M | 30.65M | 25.93M | 21.84M | 30.34M |
Operating income | -41.71M | -44.94M | -31.36M | -17.54M | -33.10M | -39.05M | -30.65M | -25.93M | -21.84M | -30.34M |
Other income (expenses), net | 2.23M | 777K | 33K | 317K | -1.08M | 641K | 216K | 8.20M | 3.13M | -9.06M |
Income before tax | -39.47M | -44.17M | -31.33M | -17.22M | -34.18M | -38.41M | -30.43M | -17.72M | -18.70M | -39.41M |
Income tax expense | 0 | -777K | -33K | -16K | -18.27M | 641K | -47K | -8.19M | -3.12M | 8.70M |
Net income | -39.47M | -43.39M | -31.3M | -17.20M | -15.91M | -38.41M | -30.43M | -17.72M | -18.70M | -39.41M |
Earnings per share | ||||||||||
Basic EPS | -13.43 | -16.5 | -12.69 | -16.95 | -30.81 | -11.52 | -12.22 | -8.52 | -9.33 | -33.72 |
Diluted EPS | -13.43 | -16.5 | -12.69 | -16.95 | -30.81 | -11.52 | -12.22 | -8.52 | -8.86 | -33.72 |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |